FDA Approves LOQTORZI™ for All Stages of Nasopharyngeal Carcinoma Treatment
Coherus BioSciences and Junshi Biosciences have announced that the U.S. Food and Drug Administration (FDA) has approved LOQTORZI™ (toripalimab-tpzi) for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). LOQTORZI is the first and only FDA-approved treatment for NPC and can be used in combination with chemotherapy for first-line treatment or as monotherapy for patients with disease progression on or after platinum-containing chemotherapy, regardless of PD-L1 status. The approval was based on positive results from Phase 2 and Phase 3 studies, which showed significant improvements in progression-free survival and overall survival. LOQTORZI is a next-generation PD-1 monoclonal antibody that activates the immune system to kill tumors.